Failure to Heed FDA Warnings of Poor Trial Design Likely To Haunt ChemoCentryx At Advisory Cmte.

 
• By Sarah Karlin-Smith
  
Woman covering her ears to block noise
ChemoCentryx failed to listen to FDA’s criticism of their pivotal study design. • Source: Aaron Amat / Alamy Stock Photo

More from US FDA Performance Tracker

More from Regulatory Trackers